The estimated Net Worth of Prahlad R. Singh is at least 5.75 百万$ dollars as of 15 May 2024. Dr Singh owns over 2,375 units of Revvity stock worth over 362,356$ and over the last 8 years he sold PKI stock worth over 526,680$. In addition, he makes 4,862,149$ as CEO、 Pres & Director at Revvity.
Dr has made over 5 trades of the Revvity stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 2,375 units of PKI stock worth 273,814$ on 15 May 2024.
The largest trade he's ever made was exercising 14,187 units of Revvity stock on 21 December 2022 worth over 694,879$. On average, Dr trades about 1,381 units every 91 days since 2017. As of 15 May 2024 he still owns at least 3,143 units of Revvity stock.
You can see the complete history of Dr Singh stock trades at the bottom of the page.
Dr. Prahlad R. Singh Ph.D. is the CEO, Pres & Director at Revvity.
As the CEO、 Pres & Director of Revvity, the total compensation of Dr D at Revvity is 4,862,149$. There are no executives at Revvity getting paid more.
Dr D is 56, he's been the CEO、 Pres & Director of Revvity since . There are 7 older and 14 younger executives at Revvity. The oldest executive at Revvity Inc. is Peter Barrett, 67, who is the Independent Director.
Prahlad's mailing address filed with the SEC is C/O AMPHENOL CORPORATION, 358 HALL AVENUE, WALLINGFORD, CT, 06492.
Over the last 26 years, insiders at Revvity have traded over 204,298,889$ worth of Revvity stock and bought 55,200 units worth 1,110,570$ . The most active insiders traders include Alexis P Michas、Gregory L Summe、Robert F Friel. On average, Revvity executives and independent directors trade stock every 25 days with the average trade being worth of 6,184,617$. The most recent stock trade was executed by Andrew Okun on 13 April 2023, trading 2,435 units of PKI stock currently worth 332,402$.
PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, the company delivers unique solutions to serve the diagnostics, life sciences, food, and applied markets. IT strategically partners with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Its dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index.
Revvity executives and other stock owners filed with the SEC include: